Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated:  12/31/1969
Dr. Rosenwasser
mi
from
Philadelphia, PA
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated: 12/31/1969
Dr. Rosenwasser
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated:  12/31/1969
Dr. Zager
mi
from
Philadelphia, PA
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated: 12/31/1969
Dr. Zager
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated:  12/31/1969
Dr. George A. Lopez
mi
from
Houston, TX
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated: 12/31/1969
Dr. George A. Lopez
mi
from
Houston, TX
Click here to add this to my saved trials
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated:  12/31/1969
Dr. Bullock
mi
from
Richmond, VA
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated: 12/31/1969
Dr. Bullock
mi
from
Richmond, VA
Click here to add this to my saved trials
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated:  12/31/1969
Dr. Wong
mi
from
Calgary,
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase IIb, Multi-center, International, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding Study for the Prevention of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage (aSAH) by Intravenous Administration of Clazosentan, a Selective Endothelin A (ETA) Receptor Antagonist
Status: Enrolling
Updated: 12/31/1969
Dr. Wong
mi
from
Calgary,
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Rogers, AR
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Rogers, AR
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
San Diego, CA
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Hialeah, FL
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Hialeah, FL
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Orlando, FL
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Tampa, FL
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Chicago, IL
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Leawood, KA
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Leawood, KA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Lincoln, NE
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Nashua, NH
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Nashua, NH
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
New York, NY
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
New York, NY
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Memphis, TN
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Irving, TX
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Irving, TX
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Spokane, WA
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Anaheim, CA
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Loxahatchee Groves, FL
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Loxahatchee Groves, FL
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Naperville, IL
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Naperville, IL
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Dallas, TX
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Houston, TX
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Houston, TX
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Everett, WA
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Everett, WA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Santa Clarita, CA
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Santa Clarita, CA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Mount Arlington, NJ
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Mount Arlington, NJ
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Sun City, AZ
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Sun City, AZ
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Orange City, FL
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Orange City, FL
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Iowa City, IA
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Voorhees, NJ
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Bronx, NY
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Bronx, NY
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Durham, NC
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Durham, NC
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
San Juan,
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
San Juan,
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
New Haven, CT
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Boston, MA
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated:  12/31/1969
Neurocrine Clinical Site
mi
from
Seattle, WA
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Status: Enrolling
Updated: 12/31/1969
Neurocrine Clinical Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Extension Connection Evaluation
Extension Connection: Dissemination Effectiveness Evaluation
Status: Enrolling
Updated:  12/31/1969
The University of Iowa College of Public Health
mi
from
Iowa City, IA
Extension Connection Evaluation
Extension Connection: Dissemination Effectiveness Evaluation
Status: Enrolling
Updated: 12/31/1969
The University of Iowa College of Public Health
mi
from
Iowa City, IA
Click here to add this to my saved trials
Treating Anorectal Dysfunction in MS
Treating Anorectal Dysfunction Associated With Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Treating Anorectal Dysfunction in MS
Treating Anorectal Dysfunction Associated With Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
(+) Epicatechin to Treat Friedreich's Ataxia
A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
(+) Epicatechin to Treat Friedreich's Ataxia
A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Paired Integrative Exercise Program for People With Dementia and Caregivers
Paired Integrative Exercise Program for People With Dementia and Caregivers
Status: Enrolling
Updated:  12/31/1969
Kaiser Oakland
mi
from
Oakland, CA
Paired Integrative Exercise Program for People With Dementia and Caregivers
Paired Integrative Exercise Program for People With Dementia and Caregivers
Status: Enrolling
Updated: 12/31/1969
Kaiser Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
Effect of Interferon Beta-1a SC 44 µg Three Times Weekly (Tiw) (Rebif) and Dimethyl Fumarate (DMF, Tecfidera) on Infections and Lymphocytes in Patients 50 Years or Older From a Single Center Chart Review
Status: Enrolling
Updated:  12/31/1969
Neurology Center of New England
mi
from
Foxboro, MA
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
Effect of Interferon Beta-1a SC 44 µg Three Times Weekly (Tiw) (Rebif) and Dimethyl Fumarate (DMF, Tecfidera) on Infections and Lymphocytes in Patients 50 Years or Older From a Single Center Chart Review
Status: Enrolling
Updated: 12/31/1969
Neurology Center of New England
mi
from
Foxboro, MA
Click here to add this to my saved trials
Pairing Word Retrieval and Physical Endurance Tasks to Treat Anomia in People With Aphasia
Pairing Word Retrieval and Physical Endurance Tasks to Treat Anomia
Status: Enrolling
Updated:  12/31/1969
Quality Living
mi
from
Omaha, NE
Pairing Word Retrieval and Physical Endurance Tasks to Treat Anomia in People With Aphasia
Pairing Word Retrieval and Physical Endurance Tasks to Treat Anomia
Status: Enrolling
Updated: 12/31/1969
Quality Living
mi
from
Omaha, NE
Click here to add this to my saved trials
Examining the Relationship Between Hormone Therapy (HT) and Cognitive Function (The WHIMS-ECHO Study)
Women's Health Initiative Memory Study--Epidemiology of Cognitive Health Outcomes
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Examining the Relationship Between Hormone Therapy (HT) and Cognitive Function (The WHIMS-ECHO Study)
Women's Health Initiative Memory Study--Epidemiology of Cognitive Health Outcomes
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
EEG Cap for Identification of Non-Convulsive Status Epilepticus
EEG Cap Placement for Expedited Identification of Non-Convulsive Status Epilepticus
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
EEG Cap for Identification of Non-Convulsive Status Epilepticus
EEG Cap Placement for Expedited Identification of Non-Convulsive Status Epilepticus
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Status: Enrolling
Updated:  12/31/1969
Memorial Hermann
mi
from
Houston, TX
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter
Status: Enrolling
Updated: 12/31/1969
Memorial Hermann
mi
from
Houston, TX
Click here to add this to my saved trials
COcoa Supplement and Multivitamin Outcomes Study for the Mind
COcoa Supplement and Multivitamin Outcomes Study-Mind
Status: Enrolling
Updated:  12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
COcoa Supplement and Multivitamin Outcomes Study for the Mind
COcoa Supplement and Multivitamin Outcomes Study-Mind
Status: Enrolling
Updated: 12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and One Appendicular Muscle in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS
An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and One Appendicular Muscle in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials